Cargando…
Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats
Chitosan is a linear polysaccharide that is made by treating the chitin shells of shrimp and crustaceans with an alkaline substance, for example sodium hydroxide. Due to its unique physical and chemical properties, chitosan has a wide range of applications in the medical field. Currently, there are...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102732/ https://www.ncbi.nlm.nih.gov/pubmed/30085342 http://dx.doi.org/10.3892/mmr.2018.9343 |
_version_ | 1783349227726831616 |
---|---|
author | Wang, Zhong-Feng Wang, Mao-Yu Yu, De-Hai Zhao, Yan Xu, Hong-Mei Zhong, Sheng Sun, Wen-Yi He, Yu-Fang Niu, Jun-Qi Gao, Pu-Jun Li, Hai-Jun |
author_facet | Wang, Zhong-Feng Wang, Mao-Yu Yu, De-Hai Zhao, Yan Xu, Hong-Mei Zhong, Sheng Sun, Wen-Yi He, Yu-Fang Niu, Jun-Qi Gao, Pu-Jun Li, Hai-Jun |
author_sort | Wang, Zhong-Feng |
collection | PubMed |
description | Chitosan is a linear polysaccharide that is made by treating the chitin shells of shrimp and crustaceans with an alkaline substance, for example sodium hydroxide. Due to its unique physical and chemical properties, chitosan has a wide range of applications in the medical field. Currently, there are no effective treatments for liver fibrosis; therefore, the aim of the present study was to investigate the therapeutic effect of chitosan in a CCl(4)-induced hepatic fibrosis (HF) rat model. The serum levels of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) were measured by ELISA. Collagen (COL) 3 and α-smooth muscle actin (SMA) expression levels in the rat liver were detected by reverse transcription-semiquantitative polymerase chain reaction and western blotting, respectively. The results demonstrated that treatment with chitosan significantly improved HF, by decreasing the serum levels of AST, ALT, and ALP; improving liver histology; and decreasing the expression levels of COL3 and α-SMA. Chitosan may offer an alternative approach for the clinical treatment of HF. |
format | Online Article Text |
id | pubmed-6102732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-61027322018-08-23 Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats Wang, Zhong-Feng Wang, Mao-Yu Yu, De-Hai Zhao, Yan Xu, Hong-Mei Zhong, Sheng Sun, Wen-Yi He, Yu-Fang Niu, Jun-Qi Gao, Pu-Jun Li, Hai-Jun Mol Med Rep Articles Chitosan is a linear polysaccharide that is made by treating the chitin shells of shrimp and crustaceans with an alkaline substance, for example sodium hydroxide. Due to its unique physical and chemical properties, chitosan has a wide range of applications in the medical field. Currently, there are no effective treatments for liver fibrosis; therefore, the aim of the present study was to investigate the therapeutic effect of chitosan in a CCl(4)-induced hepatic fibrosis (HF) rat model. The serum levels of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) were measured by ELISA. Collagen (COL) 3 and α-smooth muscle actin (SMA) expression levels in the rat liver were detected by reverse transcription-semiquantitative polymerase chain reaction and western blotting, respectively. The results demonstrated that treatment with chitosan significantly improved HF, by decreasing the serum levels of AST, ALT, and ALP; improving liver histology; and decreasing the expression levels of COL3 and α-SMA. Chitosan may offer an alternative approach for the clinical treatment of HF. D.A. Spandidos 2018-09 2018-08-01 /pmc/articles/PMC6102732/ /pubmed/30085342 http://dx.doi.org/10.3892/mmr.2018.9343 Text en Copyright: © Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wang, Zhong-Feng Wang, Mao-Yu Yu, De-Hai Zhao, Yan Xu, Hong-Mei Zhong, Sheng Sun, Wen-Yi He, Yu-Fang Niu, Jun-Qi Gao, Pu-Jun Li, Hai-Jun Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title | Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title_full | Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title_fullStr | Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title_full_unstemmed | Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title_short | Therapeutic effect of chitosan on CCl(4)-induced hepatic fibrosis in rats |
title_sort | therapeutic effect of chitosan on ccl(4)-induced hepatic fibrosis in rats |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102732/ https://www.ncbi.nlm.nih.gov/pubmed/30085342 http://dx.doi.org/10.3892/mmr.2018.9343 |
work_keys_str_mv | AT wangzhongfeng therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT wangmaoyu therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT yudehai therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT zhaoyan therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT xuhongmei therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT zhongsheng therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT sunwenyi therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT heyufang therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT niujunqi therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT gaopujun therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats AT lihaijun therapeuticeffectofchitosanonccl4inducedhepaticfibrosisinrats |